Want to see HK:0460 full AI Analyst Report?
0460 Stock Chart & Stats
HK$1.32
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.32
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.82 - HK$1.92
Previous CloseN/A
Volume8.01M
Average Volume (3M)37.54M
Market Cap
HK$8.40B
Enterprise ValueHK$4.19B
Total Cash (Recent Filing)HK$4.10B
Total Debt (Recent Filing)HK$1.01B
Price to Earnings (P/E)39.6
Beta1.06
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.21%
Share Statistics
EPS (TTM)0.02
Shares Outstanding9,329,999,000
10 Day Avg. Volume24,963,024
30 Day Avg. Volume37,542,935
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.72
Price to Sales (P/S)3.85
P/FCF Ratio-46.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$1.50Price Target Upside13.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$3.52B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 65–70% indicate durable product-level profitability and pricing power in core therapeutic areas. High gross margins provide margin cushion against input cost swings, support R&D and commercial spend, and enable operating leverage as revenues scale.
Revenue Rebound And Profit RecoveryA 21.6% revenue rebound and return to positive net income signal regained market traction and improved commercial execution. If sustained, this trend supports scale benefits, steadier hospital channel access, and the potential to convert higher sales into durable operating profitability over the medium term.
Manageable LeverageImproving debt-to-equity (~0.16) reflects a conservative balance-sheet posture, limiting interest burden and providing capacity to fund operations or strategic investments. Low leverage enhances financial flexibility to absorb cyclical shocks and supports longer-term investment in pipelines or commercialization.
Bears Say
Weak Cash-flow GenerationNegative operating cash flow and deeply negative free cash flow in 2025 signal poor cash conversion despite reported net income, raising quality-of-earnings concerns. Persistent cash deficits constrain capex, R&D or working-capital funding and increase reliance on external financing over the medium term.
Earnings VolatilityMulti-year swings, including a large 2022 loss and 2024 negative margins, indicate unstable earnings driven by demand, pricing or one-off items. Such volatility complicates forecasting, weakens confidence with payers/hospitals, and makes it harder to rely on profits for sustained reinvestment or dividends.
Low Return On EquityA ~3% ROE shows the company is not yet translating asset or equity base into robust shareholder returns. Even with a solid balance sheet, low ROE implies limited capital efficiency and suggests structural work is needed on product mix, pricing or cost structure to improve long-term investor returns.
Sihuan Pharmaceutical Holdings Group News
0460 FAQ
What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?
Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was HK$0.82 and its highest was HK$1.92 in the past 12 months.
What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?
Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is HK$8.40B.
When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?
Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 41 days.
How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?
Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.009 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.009.
Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?
According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Undervalued.
Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?
Sihuan Pharmaceutical Holdings Group Ltd. pays a Annually dividend of HK$0.011 which represents an annual dividend yield of 1.21%. See more information on Sihuan Pharmaceutical Holdings Group Ltd. dividends here
What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?
Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?
Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.
What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?
Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of HK$0.009 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.512%.
Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?
Currently, no hedge funds are holding shares in HK:0460
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sihuan Pharmaceutical Holdings Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.00%
12-Months-Change
Fundamentals
Return on Equity
1.21%
Trailing 12-Months
Asset Growth
15.37%
Trailing 12-Months
Company Description
Sihuan Pharmaceutical Holdings Group Ltd.
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China and the United States. It operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions. It also provides drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. In addition, the company involved in the provision of research and development, and industrialization of innovative medicine; construction for medical project; provision of general hospital services and hospital management services; and property investment business. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.
0460 Stock 12 Month Forecast
Average Price Target
HK$1.50
▲(13.64% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―







